Loading…

Intrathecal baclofen pumps in the management of hypertonia in childhood: a UK and Ireland wide survey

BackgroundIntrathecal baclofen (ITB) is a useful treatment for hypertonia where non-invasive treatments have been ineffective or poorly tolerated. There is an absence of national guidance on selection criteria and a lack of literature regarding patient characteristics and treatment details for child...

Full description

Saved in:
Bibliographic Details
Published in:Archives of disease in childhood 2021-12, Vol.106 (12), p.1202-1206
Main Authors: Lodh, Rajib, Amin, Sam, Ammar, Amr, Bellis, Lucy, Brink, Phillip, Calisto, Amedeo, Crimmins, Darach, Eunson, Paul, Forsyth, Rob J, Goodden, John, Kaminska, Margaret, Kehoe, Joanne, Kirkpatrick, Martin, Kumar, Ram, Leonard, Jane, Lording, Alice, Martin, Katherine, Miller, Russell, Mordekar, Santosh R, Pettorini, Benedetta, Smith, Martin, Smith, Rachel, Sneade, Christine, Whitney, Andrea, Vloeberghs, Michael, Zaki, Hesham, Lumsden, Daniel E
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundIntrathecal baclofen (ITB) is a useful treatment for hypertonia where non-invasive treatments have been ineffective or poorly tolerated. There is an absence of national guidance on selection criteria and a lack of literature regarding patient characteristics and treatment details for children and young people (CYP) receiving ITB therapy in the UK and Ireland. We aimed to gather patient and treatment characteristics for CYP receiving ITB in the UK and Ireland.MethodsAn electronic survey was sent to all paediatric ITB centres in the UK and Ireland. Anonymised data were returned between December 2019 and April 2020. CYP >16 years and those awaiting ITB pump removal were excluded from the dataset.Results176 CYP were identified as receiving ITB therapy across the UK and Ireland. The majority of CYP with ITB pumps were non-ambulant (93%) with a diagnosis of cerebral palsy (79%). Median age of ITB insertion was 9 years; median current age was 14 years. 79% of CYP had significant spasticity, 55% had significant dystonia. The most commonly used ITB dosing modes were continuous (73%) and flexible (23%).ConclusionsITB pumps were most frequently used for non-ambulant CYP with cerebral palsy and existence of spasticity and/or dystonia in the UK and Ireland. Most CYP were receiving a continuous dose of ITB. There is significant variation in the number of paediatric ITB pumps across UK and Ireland. There is a need for development of nationally accepted paediatric referral criteria and clinical standards for ITB use.
ISSN:0003-9888
1468-2044
DOI:10.1136/archdischild-2020-321487